BRPI0815576A2 - Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. - Google Patents

Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.

Info

Publication number: BRPI0815576A2
Authority: BR; Brazil
Prior art keywords: cell line; progene; vector; producing; polynucleotide sequence
Prior art date: 2007-08-20

Application number

Other languages

English (en)

Inventor

Mark Uden

Ekaterini Kotsopoulou

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-20

Filing date

2008-08-19

Publication date

2015-02-18

2008-08-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2015-02-18 Publication of BRPI0815576A2 publication Critical patent/BRPI0815576A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0815576 2007-08-20 2008-08-19 Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. BRPI0815576A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US95677207P	2007-08-20	2007-08-20
PCT/EP2008/060834 WO2009024567A1 (en)	2007-08-20	2008-08-19	Production method

Publications (1)

Publication Number	Publication Date
BRPI0815576A2 true BRPI0815576A2 (pt)	2015-02-18

Family

ID=40070558

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815576 BRPI0815576A2 (pt)	2007-08-20	2008-08-19	Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.

Country Status (13)

Country	Link
US (2)	US9163249B2 (pt)
EP (3)	EP3216802B1 (pt)
JP (2)	JP5592258B2 (pt)
KR (1)	KR101637533B1 (pt)
CN (1)	CN101848936B (pt)
AU (1)	AU2008290607B2 (pt)
BR (1)	BRPI0815576A2 (pt)
CA (1)	CA2695484C (pt)
DK (1)	DK3216802T3 (pt)
EA (1)	EA022990B1 (pt)
ES (2)	ES2840725T3 (pt)
MX (1)	MX2010002003A (pt)
WO (1)	WO2009024567A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2840725T3 (es) *	2007-08-20	2021-07-07	Glaxo Group Ltd	Procedimiento de producción
CN102741421B (zh) *	2009-03-10	2015-03-25	帝斯曼知识产权资产管理有限公司	用于提高多肽产率的方法
CA2784861A1 (en) *	2009-12-21	2011-07-14	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
JP6039552B2 (ja)	2010-07-01	2016-12-07	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	高産生細胞株を選択するための改良された方法
GB201112429D0 (en)	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
BR112015017619A2 (pt)	2013-01-24	2017-11-21	Glaxosmithkline Ip Dev Ltd	formulação líquida, uso de uma formulação, e, kit
SG11201802408RA (en) *	2015-11-05	2018-05-30	Bamboo Therapeutics Inc	Modified friedreich ataxia genes and vectors for gene therapy
WO2017162266A1 (en)	2016-03-21	2017-09-28	Biontech Rna Pharmaceuticals Gmbh	Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en)	2016-03-21	2017-09-28	Biontech Rna Pharmaceuticals Gmbh	Trans-replicating rna
EP3681993B1 (en)	2017-09-13	2026-04-01	BioNTech SE	Rna replicon for reprogramming somatic cells
EP3681904A1 (en)	2017-09-13	2020-07-22	Biontech Cell&Gene Therapies GmbH	Rna replicon for expressing a t cell receptor or an artificial t cell receptor
JP7769644B2 (ja)	2020-06-04	2025-11-13	バイオエヌテックエスエー	多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン
EP4419695A1 (en)	2021-10-18	2024-08-28	BioNTech SE	Modified replicable rna and related compositions and their use
EP4419708A1 (en)	2021-10-18	2024-08-28	BioNTech SE	Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
WO2023213378A1 (en)	2022-05-02	2023-11-09	BioNTech SE	Replicon compositions and methods of using same for the treatment of diseases
WO2024017479A1 (en)	2022-07-21	2024-01-25	BioNTech SE	Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
CA3267295A1 (en)	2022-09-15	2024-03-21	TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH-Aysegul YILDIZ	SYSTEMS AND COMPOSITIONS CONTAINING TRANS-AMPLIFYING RNA VECTORS WITH MIARN
WO2024165146A1 (en)	2023-02-07	2024-08-15	Biontech Cell & Gene Therapies Gmbh	Immune effector cells stably and transiently expressing nucleic acids
CN120936375A (zh)	2023-04-14	2025-11-11	生物技术欧洲股份公司	Hiv疫苗
IL326711A (en)	2023-08-24	2026-04-01	BioNTech SE	Systems and compositions comprising highly active trans-amplifying replicases
WO2025051381A1 (en)	2023-09-08	2025-03-13	BioNTech SE	Methods and compositions for localized expression of administered rna

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0953639A1 (en) *	1998-04-30	1999-11-03	Boehringer Ingelheim International GmbH	FAPalpha-specific antibody with improved producibility
AU2002256005A1 (en) *	2001-03-27	2002-10-08	Smithkline Beecham Corporation	Control of glycoforms in igg
US20040146512A1 (en) *	2002-10-09	2004-07-29	Arnon Rosenthal	Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
WO2004046168A2 (en) *	2002-11-15	2004-06-03	The Henry M. Jackson Foundation	Recombinant hiv-1 subclass d envelope glycoproteins
US7384744B2 (en) *	2002-11-29	2008-06-10	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7485297B2 (en)	2003-08-12	2009-02-03	Dyax Corp.	Method of inhibition of vascular development using an antibody
WO2005111623A1 (en) *	2004-05-17	2005-11-24	Crucell Holland B.V.	Methods for diagnosis of acute myeloid leukemia
US7462697B2 (en) *	2004-11-08	2008-12-09	Epitomics, Inc.	Methods for antibody engineering
EP1838348B1 (en) *	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Humanized amyloid beta antibodies for use in improving cognition
US7906625B2 (en) *	2005-01-24	2011-03-15	Amgen Inc.	Humanized anti-amyloid antibody
EP1915394B1 (en) *	2005-05-20	2021-01-27	Lonza Biologics plc.	High-level expression of recombinant antibody in a mammalian host cell
MY155286A (en)	2005-12-12	2015-09-30	Hoffmann La Roche	Antibodies against amyloid beta 4 with glycosylated in the variable region
US8101727B2 (en) *	2006-03-30	2012-01-24	Novartis Ag	Compositions and methods of use for antibodies of c-Met
JP5103466B2 (ja) *	2006-03-30	2012-12-19	グラクソグループリミテッド	アミロイド‐βペプチドに対する抗体
ES2840725T3 (es) *	2007-08-20	2021-07-07	Glaxo Group Ltd	Procedimiento de producción

2008
- 2008-08-19 ES ES17159323T patent/ES2840725T3/es active Active
- 2008-08-19 AU AU2008290607A patent/AU2008290607B2/en not_active Ceased
- 2008-08-19 BR BRPI0815576 patent/BRPI0815576A2/pt not_active Application Discontinuation
- 2008-08-19 WO PCT/EP2008/060834 patent/WO2009024567A1/en not_active Ceased
- 2008-08-19 US US12/674,069 patent/US9163249B2/en active Active
- 2008-08-19 DK DK17159323.9T patent/DK3216802T3/da active
- 2008-08-19 JP JP2010521409A patent/JP5592258B2/ja active Active
- 2008-08-19 KR KR1020107006104A patent/KR101637533B1/ko active Active
- 2008-08-19 ES ES08787316.2T patent/ES2473623T3/es active Active
- 2008-08-19 EP EP17159323.9A patent/EP3216802B1/en active Active
- 2008-08-19 EP EP20080787316 patent/EP2185591B1/en active Active
- 2008-08-19 MX MX2010002003A patent/MX2010002003A/es not_active Application Discontinuation
- 2008-08-19 EA EA201000205A patent/EA022990B1/ru not_active IP Right Cessation
- 2008-08-19 EP EP20120171016 patent/EP2527367A1/en not_active Withdrawn
- 2008-08-19 CN CN200880111547.1A patent/CN101848936B/zh active Active
- 2008-08-19 CA CA2695484A patent/CA2695484C/en not_active Expired - Fee Related
2014
- 2014-07-31 JP JP2014155890A patent/JP6029625B2/ja active Active
2015
- 2015-09-30 US US14/870,065 patent/US10633673B2/en active Active

Also Published As

Publication number	Publication date
AU2008290607A1 (en)	2009-02-26
ES2840725T3 (es)	2021-07-07
EP3216802B1 (en)	2020-10-07
WO2009024567A1 (en)	2009-02-26
US20160010111A1 (en)	2016-01-14
EP3216802A1 (en)	2017-09-13
EP2185591A1 (en)	2010-05-19
JP2010536358A (ja)	2010-12-02
KR101637533B1 (ko)	2016-07-11
CA2695484C (en)	2018-05-01
MX2010002003A (es)	2010-03-10
US10633673B2 (en)	2020-04-28
KR20100065332A (ko)	2010-06-16
CA2695484A1 (en)	2009-02-26
EP2185591B1 (en)	2014-05-14
ES2473623T3 (es)	2014-07-07
CN101848936B (zh)	2017-05-03
DK3216802T3 (da)	2021-01-04
EP2527367A1 (en)	2012-11-28
JP5592258B2 (ja)	2014-09-17
JP6029625B2 (ja)	2016-11-24
US20110040074A1 (en)	2011-02-17
US9163249B2 (en)	2015-10-20
JP2015027298A (ja)	2015-02-12
EA022990B1 (ru)	2016-04-29
EA201000205A1 (ru)	2011-02-28
CN101848936A (zh)	2010-09-29
AU2008290607B2 (en)	2013-11-14

Publication	Publication Date	Title
BRPI0815576A2 (pt)	2015-02-18	Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.
BRPI0813242A2 (pt)	2015-08-18	Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
ITRM20040447A1 (it)	2004-12-22	Sistema di fornitura di seminari interattivi, e relativo metodo.
BRPI0819842A2 (pt)	2015-06-16	Sistema de carga e método para operar o mesmo.
NO20073935L (no)	2009-01-28	Tetningsarrangement, samt tilhorende fremgangsmate
BRPI0811610A2 (pt)	2014-11-04	Aço com baixa densidade, apresentando uma boa aptidão ao encaixe
ATE527385T1 (de)	2011-10-15	Mit tumoren assoziierte genetische variationen
BRPI0813216A2 (pt)	2014-12-23	Inibidores de proteínas cinases e métodos para usá-los.
BRPI0810194A2 (pt)	2014-12-30	Método para gestão de mobilidade em uma arquitetura de sistema de apoio à mobilidade entre diferentes sistemas de acesso.
BRPI0810356A2 (pt)	2014-10-21	Sistema de aquecimento para uma formação de subsuperfície, e, método para aquecer uma formação de subsuperfície.
BRPI0716439A2 (pt)	2013-09-17	formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0822078A2 (pt)	2015-06-23	Método, e, sistema.
BRPI0819714A2 (pt)	2015-05-26	Formulações de proteína e métodos de produção das mesmas.
NL2000627A1 (nl)	2007-11-12	Cycloalkylaminoderivaten.
ITVE20060045A1 (it)	2008-01-14	Dispositivo riscaldatore per calzature, guanti e simili.
BRPI0714170A2 (pt)	2014-11-18	Processos para a fabricação de 1,2-dicloroetano, de cloreto de vinila, e de cloreto de polivinila.
BRPI0810710A2 (pt)	2014-10-21	Método para estabilização de uma proteína.
BRPI0716068A2 (pt)	2014-01-21	Bactéria recombinante, e, métodos para produzir bactéria recombinante e etanol a partir de uma fonte de oligossacarídeo, kit, e, e. coli
BRPI0810190A2 (pt)	2014-12-30	Sistema, e, método.
BRPI0719272A2 (pt)	2014-04-29	Composição de enzima, e, método para preparar uma composição de enzima.
BRPI0811492B8 (pt)	2018-05-08	método para produzir uma bebida láctea acidificada, bebida láctea acidificada, e, polipeptídeo isolado com atividade desamidase
BRPI0920989A2 (pt)	2016-01-05	sistema de criação de plano de combinação e dotação de navio, método e programa para o mesmo
BRPI0915289A2 (pt)	2016-02-16	inserto para solas, sola, e, calçado.
BRPI1013484A2 (pt)	2015-08-25	"protease, dna, vetor de expressão , célula transformada, e, método para produzir uma protease".
EP2058295A4 (en)	2011-03-30	Imide complex, method for producing the same, metal-containing thin film and method for producing the same

Legal Events

Date	Code	Title	Description
2017-03-28	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-11-07	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-09-04	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-04-09	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-08-06	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-10-22	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL